Products
Glecaprevir was approved in the United States, many countries, and the EU in 2017 as a fixed-dose combination with pibrentasvir in film-coated tablet form (Maviret).
Structure and properties
Glecaprevir (C38H46F4N6O9S, Mr = 838.9 g/mol) exists as a white crystalline powder.
Effects
Glecaprevir has antiviral properties. The effects are due to inhibition of the viral HCV NS3/4A protease, which is responsible for cleavage of the HCV polyprotein. As a result, viral replication is inhibited.
Indications
For the treatment of chronic hepatitis C (genotypes 1, 2, 3, 4, 5, or 6).
Dosage
According to the SmPC. Tablets are taken once daily with food.
Contraindications
For complete precautions, see the drug label.
Interactions
There is a potential for drug-drug interactions. Glecaprevir is a substrate of P-glycoprotein, BCRP, OATP1B1/3, and CYP3A4.
Adverse effects
The most common potential adverse effects of combination therapy include headache, fatigue, and nausea.
